{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:40:34Z","timestamp":1762508434205,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eisai Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It was reported that eribulin regulates the tumor microenvironment, including the immune system, by inducing vascular remodeling. Lymphocyte counts are a critical index of immune response in patients. The non-Asian, global EMBRACE study has suggested that baseline absolute lymphocyte count (ALC) may be a predictor of the survival benefit of eribulin in breast cancer patients. We examined whether the baseline ALC is a potential predictor of overall survival (OS) in Japanese patients with HER2-negative advanced breast cancer treated with eribulin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a post hoc analysis of data from a post-marketing observational study of eribulin in Japan. The OS by baseline ALC was estimated using the Kaplan\u2013Meier method, with the cut-off value of 1500\/\u03bcL for ALC. The OS by baseline neutrophil-to-lymphocyte ratio (NLR), a general prognostic index in breast cancer patients, was also estimated, with the cut-off value of 3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median OS was longer in patients with an ALC of\u2009\u2265\u20091500\/\u03bcL than in those with an ALC of\u2009&lt;\u20091500\/\u03bcL (19.4 vs. 14.3\u00a0months; hazard ratio [HR]: 0.628; 95% confidence interval [CI]: 0.492, 0.801). Patients with an NLR of\u2009\u2265\u20093 showed shorter OS than those with an NLR of\u2009&lt;\u20093 (13.2 vs. 18.8\u00a0months; HR: 1.552; 95% CI 1.254, 1.921), and NLR also separated OS in patients with an ALC of\u2009&lt;\u20091500\/\u03bcL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Consistent with the findings of a previous study involving a non-Asian, Western population, our study suggested that baseline ALC may be a predictive factor for the survival benefit of eribulin in Japanese patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12282-021-01232-1","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T14:02:36Z","timestamp":1615125756000},"page":"945-955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9598","authenticated-orcid":false,"given":"Masato","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyomi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Muramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,7]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323.","journal-title":"Lancet"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594\u2013601.","journal-title":"J Clin Oncol"},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10637-017-0486-4","volume":"35","author":"J Watanabe","year":"2017","unstructured":"Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Invest New Drugs. 2017;35:791\u20139.","journal-title":"Invest New Drugs"},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12282-018-0919-8","volume":"26","author":"J Tsurutani","year":"2019","unstructured":"Tsurutani J, Sakata Y, Matsuoka T. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study. Breast Cancer. 2019;26:235\u201343.","journal-title":"Breast Cancer"},{"key":"1232_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s10637-019-00890-5","volume":"38","author":"K Inoue","year":"2020","unstructured":"Inoue K, Takahashi M, Mukai H, Yamanaka T, Egawa C, Sakata Y, et al. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38:1540\u20139.","journal-title":"Invest New Drugs"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clbc.2018.03.002","volume":"18","author":"Y Miyagawa","year":"2018","unstructured":"Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with Nab-paclitaxel. Clin Breast Cancer. 2018;18:400\u20139.","journal-title":"Clin Breast Cancer"},{"key":"1232_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer. 2020;27:706\u201315.","journal-title":"Breast Cancer"},{"key":"1232_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal\u2013epithelial transition (MET) states. Br J Cancer. 2014;110:1497\u2013505.","journal-title":"Br J Cancer"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105:1334\u201342.","journal-title":"Cancer Sci"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","volume":"114","author":"S Ueda","year":"2016","unstructured":"Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer. 2016;114:1212\u20138.","journal-title":"Br J Cancer"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.13392","volume":"108","author":"K Ito","year":"2017","unstructured":"Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, et al. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci. 2017;108:2273\u201380.","journal-title":"Cancer Sci"},{"key":"1232_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-019-0521-x","volume":"9","author":"S Zhao","year":"2019","unstructured":"Zhao S, Yu W, Ukon N, Tan C, Nishijima KI, Shimizu Y, et al. Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models. EJNMMI Res. 2019;9:51.","journal-title":"EJNMMI Res"},{"key":"1232_CR13","first-page":"2929","volume":"38","author":"W Goto","year":"2018","unstructured":"Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Fujita H, et al. Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer. Anticancer Res. 2018;38:2929\u201338.","journal-title":"Anticancer Res"},{"key":"1232_CR14","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383\u201391.","journal-title":"Cancer Res"},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/bjc.2015.183","volume":"113","author":"CH Koh","year":"2015","unstructured":"Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113:150\u20138.","journal-title":"Br J Cancer"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-018-4888-2","volume":"18","author":"K Araki","year":"2018","unstructured":"Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 2018;18:982.","journal-title":"BMC Cancer"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe J, Saito M, Horimoto Y, Nakamoto S. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res Treat. 2020;181:211\u201320.","journal-title":"Breast Cancer Res Treat"},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000507043","volume":"64","author":"A Ueno","year":"2019","unstructured":"Ueno A, Maeda R, Kin T, Ito M, Kawasaki K, Ohtani S. Utility of the absolute lymphocyte count and neutrophil\/lymphocyte ratio for predicting survival in patients with metastatic breast cancer on eribulin: a real-world observational study. Chemotherapy. 2019;64:259\u201369.","journal-title":"Chemotherapy"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s12282-020-01069-0","volume":"27","author":"M Myojin","year":"2020","unstructured":"Myojin M, Horimoto Y, Ito M, Kitano S, Ishizuka Y, Sasaki R, et al. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast Cancer. 2020;27:732\u20138.","journal-title":"Breast Cancer"},{"key":"1232_CR20","doi-asserted-by":"publisher","first-page":"16979","DOI":"10.1038\/s41598-019-53606-3","volume":"9","author":"A Ivars Rubio","year":"2019","unstructured":"Ivars Rubio A, Yufera JC, de la Morena P, Fern\u00e1ndez S\u00e1nchez A, Navarro Manzano E, Garc\u00eda Garre E, et al. Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables. Sci Rep. 2019;9:16979.","journal-title":"Sci Rep"},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.23217","volume":"8","author":"A Diehl","year":"2017","unstructured":"Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 2017;8:114268\u201380.","journal-title":"Oncotarget"},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/1346-8138.14865","volume":"46","author":"Y Muto","year":"2019","unstructured":"Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, et al. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. J Dermatol. 2019;46:498\u2013506.","journal-title":"J Dermatol"},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.24951","volume":"116","author":"GY Ku","year":"2010","unstructured":"Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Version 2. Cancer. 2010;116:1767\u201375.","journal-title":"Cancer"},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.21873\/anticanres.14317","volume":"40","author":"S Kashiwagi","year":"2020","unstructured":"Kashiwagi S, Asano Y, Goto W, Takada K, Morisaki T, Kouhashi R, et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40:3345\u201354.","journal-title":"Anticancer Res"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3727\/105221611X13176664479322","volume":"15","author":"MA Taylor","year":"2011","unstructured":"Taylor MA, Lee YH, Schiemann WP. Role of TGF-beta and the tumor microenvironment during mammary tumorigenesis. Gene Expr. 2011;15:117\u201332.","journal-title":"Gene Expr"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-021-01232-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-021-01232-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-021-01232-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T15:27:32Z","timestamp":1624030052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-021-01232-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1007\/s12282-021-01232-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"type":"print","value":"1340-6868"},{"type":"electronic","value":"1880-4233"}],"subject":[],"published":{"date-parts":[[2021,3,7]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Takahashi received honoraria from AstraZeneca, Eli Lilly, and Pfizer; and received research funding from Taiho and Kyowa Hakko Kirin. K. Inoue received grants from Novartis, Pfizer, Chugai, Daiichi-Sankyo, Parexel\/Puma Biotechnology, MSD, Bayer, Eli Lilly, AstraZeneca, Sanofi, and Eisai; and received personal fees from Eisai, Chugai, Pfizer, and Eli Lilly. H. Mukai received grants from Eisai, Daiichi Sankyo, Pfizer, Japanese Government, and Nippon Kayaku; and personal fees from Eisai, Daiichi Sankyo, Pfizer, AstraZeneca, Taiho, and Takeda. T. Yamanaka received honoraria from Chugai, Eisai, Daiichi-Sankyo, Novartis, Pfizer, Kyowa-Kirin, and Eli Lilly. C. Egawa declares no conflicts of interest. Y. Miyoshi received grants from Eisai, Chugai, MSD, Kyowa-Kirin, Eli Lilly, and Taiho; and personal fees from Eisai, Chugai, AstraZeneca, Eli Lilly, and Pfizer. Y. Sakata, K. Muramoto, H. Ikezawa, and T. Matsuoka are employees of Eisai Co., Ltd. J. Tsurutani is an adviser of Eisai Co., Ltd., Asahi Kasei Corporation, and Daiichi Sankyo; received honoraria from Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Roche Diagnostics K.K., Novartis Pharma, AstraZeneca K.K., and Kyowa-Kirin; received research funds from Eisai Co., Ltd. and Taiho Pharmaceutical Co., Ltd.; and his institution received donations from Eisai, Chugai, Daiichi-Sankyo, Nihonkayaku, Eli Lilly, Boehringer Ingelheim, MSD, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Japanese Good Post-Marketing Study Practice (GPSP), which is an authorized standard for post-marketing surveillance. GPSP does not require approval from the institutional review boards of each institution. However, in practice, some institutions may have obtained approval when deemed necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"GPSP does not require approval from each institution\u2019s institutional review board or informed consent from the participating patients. Therefore, obtaining informed consent was not mandatory for this type of study. However, in some institutions, informed consent may have been obtained from participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}